XML 20 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 6 Months Ended 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2021
Dec. 31, 2020
Jun. 30, 2020
Jun. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:            
Net income (loss) attributable to Myriad Genetics, Inc. stockholders $ (53.1) $ (28.9) $ (27.2) $ (223.6) $ (199.5) $ 4.6
Adjustments to reconcile net income (loss) to net cash provided by operating activities:            
Depreciation and amortization 35.8   62.8   72.0 73.0
Non-cash interest expense 0.4   1.5   0.5 0.4
Non-cash lease expense 6.4   12.8   0.0 0.0
Stock-based compensation expense 14.9   36.3   25.2 33.5
Deferred income taxes 44.2   (32.1)   (55.8) 18.6
Unrecognized tax benefits 7.1   (2.6)   1.7 (5.5)
Non-cash impact of foreign currency transactions (1.0)   0.0   0.0 0.0
Loss on inventory 0.0   6.5   0.0 0.0
Impairment of goodwill and long-lived assets 0.0 1.3 1.8 98.4 99.7 0.0
Gain on sale of businesses and assets 0.0   (162.0)   (1.0) 0.0
Payment of contingent consideration 0.0   0.0   0.0 (1.5)
Changes in assets and liabilities:            
Prepaid expenses and other current assets 3.1   (6.6)   2.8 (3.9)
Trade accounts receivable (21.4)   (8.8)   64.0 (18.2)
Inventory 2.2   1.6   1.6 8.0
Prepaid taxes (108.4)   89.9   25.1 (25.1)
Other assets (2.3)   (4.0)   0.0 0.0
Accounts payable (1.2)   9.2   (10.7) 1.1
Accrued liabilities (0.2)   65.7   4.4 (0.8)
Deferred revenue (0.2)   (26.6)   30.7 (0.5)
Net cash provided by (used in) operating activities (73.7)   18.2   60.7 83.7
CASH FLOWS FROM INVESTING ACTIVITIES:            
Capital expenditures (7.9)   (18.0)   (10.2) (8.6)
Acquisitions, net of cash acquired 0.0   0.0   0.0 (278.5)
Proceeds from sale of business and assets 0.0   379.1   21.3 0.0
Purchases of marketable investment securities 0.0   (147.8)   (60.8) (78.5)
Proceeds from maturities and sales of marketable investment securities 35.9   61.1   69.0 79.2
Net cash provided by (used in) investing activities 28.0   274.4   19.3 (286.4)
CASH FLOWS FROM FINANCING ACTIVITIES:            
Proceeds from common stock issued under stock-based compensation plans 1.8   91.8   13.3 23.2
Payment of tax withheld for common stock issued under stock-based compensation plans (3.8)   (11.5)   (9.8) (14.5)
Payment of contingent consideration recognized at acquisition (0.1)   (3.3)   (3.9) 0.0
Proceeds from revolving credit facility 0.0   0.0   0.0 340.0
Fees associated with refinancing of revolving credit facility 0.0   (1.2)   (1.0) (1.4)
Repayment of revolving credit facility 0.0   (226.4)   (8.6) (115.0)
Repurchase and retirement of common stock 0.0   0.0   0.0 (50.0)
Net cash provided by (used in) financing activities (2.1)   (150.6)   (10.0) 182.3
Effect of foreign exchange rates on cash and cash equivalents 1.1   (0.6)   0.5 2.7
Net increase (decrease) in cash and cash equivalents (46.7)   141.4   70.5 (17.7)
Cash and cash equivalents at beginning of the period 163.7 $ 93.2 117.0   93.2 110.9
Cash and cash equivalents at end of the period $ 117.0   $ 258.4 $ 117.0 $ 163.7 $ 93.2